Inventor · disambiguated record
Erik I. Tucker
Also filed as: TUCKER ERIK · TUCKER ERIK I · TUCKER ERIK IAN
16 granted patents·5 pending applications·152 citations·filing 2008–2024
93Inventor score
Top patents by PatentIndex Score
21 records- 0195US9636399B2Anti-factor XI monoclonal antibodies and methods of use thereofUNIV OREGON HEALTH & SCIENCE·Filed 2015·Granted May 2, 2017·15 cites·22 claims
- 0295US8236316B2Anti-factor XI monoclonal antibodies and methods of use thereofGRUBER ANDRAS·Filed 2008·Granted Aug 7, 2012·33 cites·24 claims
- 0394US9125895B2Anti-factor XI monoclonal antibodies and methods of use thereofUNIV OREGON HEALTH & SCIENCE·Filed 2014·Granted Sep 8, 2015·19 cites·15 claims
- 0493US8388959B2Anti-fXI antibodies and methods of useGRUBER ANDRAS·Filed 2009·Granted Mar 5, 2013·29 cites·22 claims
- 0591US9637550B2Anti-fXI antibodies and methods of useUNIV OREGON HEALTH & SCIENCE·Filed 2014·Granted May 2, 2017·14 cites·21 claims
- 0691US8940883B2Anti-fXI antibodies and methods of useUNIV OREGON HEALTH & SCIENCE·Filed 2013·Granted Jan 27, 2015·15 cites·12 claims
- 0791US8399648B2Polynucleotides encoding anti-factor XI monoclonal antibodies and methods of use thereofGRUBER ANDRAS·Filed 2012·Granted Mar 19, 2013·14 cites·14 claims
- 0885US10221247B2Antibodies capable of binding to the coagulation factor XIa and uses thereofBayer Pharma AG·Filed 2017·Granted Mar 5, 2019·5 cites·12 claims
- 0985US9783614B2Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereofBayer Pharma AG·Filed 2013·Granted Oct 10, 2017·7 cites·6 claims
- 1074US10040866B2Nucleic acids and host cells expressing antibodies capable of binding to the coagulation factor XIa and uses thereofBayer Pharma AG·Filed 2017·Granted Aug 7, 2018·1 cites·12 claims
- 1169US10577428B2Anti-factor XI monoclonal antibodies and methods of use thereofUNIV OREGON HEALTH & SCIENCE·Filed 2018·Granted Mar 3, 2020·0 cites·19 claims
- 1267US11046783B2Antibodies capable of binding to the coagulation factor XIa and uses thereofBayer Pharma AG·Filed 2019·Granted Jun 29, 2021·0 cites·16 claims
- 1362US2017204195A1Anti-factor xi monoclonal antibodies and methods of use thereofUNIV OREGON HEALTH & SCIENCE·Filed 2017·Application pending·0 cites
- 1462US2013171144A1Anti-factor xi monoclonal antibodies and methods of use thereofUNIV OREGON HEALTH & SCIENCE·Filed 2013·Application pending·0 cites
- 1559US2024409667A1Inhibition of contact pathway activation for the treatment of neuroinflammationUNIV OREGON HEALTH & SCIENCE·Filed 2024·Application pending·0 cites
- 1654US12134657B2Therapeutic factor XII antibodyUNIV OREGON HEALTH & SCIENCE·Filed 2019·Granted Nov 5, 2024·0 cites·21 claims
- 1752US12496311B2Methods for safely reducing thrombopoietinARONORA INC·Filed 2019·Granted Dec 16, 2025·0 cites·16 claims
- 1843US10654941B2Antibodies against factor XI and uses thereofBayer Pharma AG·Filed 2017·Granted May 19, 2020·0 cites·20 claims
- 1939US2022089777A1Novel humanized antibodies against factor xi having anti-thrombotic and anti-inflammatory effect and uses thereofARONORA INC·Filed 2020·Application pending·0 cites
- 2029US10137177B2Methods and compositions used in treating inflammatory and autoimmune diseasesUNIV OREGON HEALTH & SCIENCE·Filed 2015·Granted Nov 27, 2018·0 cites·12 claims
- 2129US2020054719A1E-we thrombin analog and fibrinolytic combinationTUCKER ERIK IAN·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Erik I. Tucker files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →